In vivo 31 P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial

F. Arias-Mendoza, G. S. Payne, K. L. Zakian, A. J. Schwarz, M. Stubbs, R. Stoyanova, D. Ballon, F. A. Howe, J. A. Koutcher, M. O. Leach, J. R. Griffiths, A. Heerschap, J. D. Glickson, S. J. Nelson, J. L. Evelhoch, H. C. Charles, T. R. Brown, J. Cruz-Lobo, J. Murphy-Boesch, W. G. NegendankA. Shukla-Dave, A. Oregioni, D. J. Collins, N. R. Maisey, Sabrina Ronen, Victoria L. Doyle, Mark Rijpkema, H. Poptani, R. E. Lenkinski, D. B. Vigneron, Jiani Hu

Research output: Contribution to journalArticle

41 Scopus citations

Abstract

The standardization and reproducibility of techniques required to acquire anatomically localized 31p MR spectra non-invasively while studying tumors in cancer patients in a multi-institutional group at 1.5 Tare reported. This initial group of patients was studied from 1995 to 2000 to test the feasibility of acquiring in vivo localized 31P MRS in clinical MR spectrometers. The cancers tested were non-Hodgkin's lymphomas, sarcomas of soft tissue and bone, breast carcinomas and head and neck carcinomas. The best accrual and spectral quality were achieved with the non-Hodgkin's lymphomas. The initial analysis of the spectral values of the sum of phosphoethanolamine plus phosphocholine normalized by the content of nucleotide triphosphates in a homogeneous sample of 32 NHL patients studied by in vivo 31P MRS showed good reproducibility among different institutions. No statistical differences were found between the institution with the largest number of cases accrued and the rest of the multi-institutional NHL data (2.2 ± 0.64, mean ± standard error; n = 17, vs 2.08 ± 0.14, n = 15). The preliminary data reported demonstrate that the institutions involved in this trial are obtaining reproducible 31P MR spectroscopic data non-invasively from human tumors. This is a fundamental prerequisite for the international cooperative group to be able to demonstrate the clinical value of the normalized determination of phosphoethanolamine plus phosphocholine by 31P MRS as predictor for treatment response in cancer patients.

Original languageEnglish (US)
Pages (from-to)504-512
Number of pages9
JournalNMR in biomedicine
Volume19
Issue number4
DOIs
StatePublished - Jun 2006

Keywords

  • Breast carcinomas
  • Cancer
  • Head and neck carcinomas
  • Localized P MR spectroscopy
  • Multi-institutional group
  • Non-Hodgkin's lymphomas
  • Non-invasive
  • Phosphocholine
  • Phosphoethanolamine
  • Reproducibility
  • Sarcomas of soft tissue and bone

ASJC Scopus subject areas

  • Spectroscopy
  • Radiology Nuclear Medicine and imaging
  • Radiological and Ultrasound Technology
  • Biophysics

Fingerprint Dive into the research topics of 'In vivo <sup>31</sup> P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial'. Together they form a unique fingerprint.

  • Cite this

    Arias-Mendoza, F., Payne, G. S., Zakian, K. L., Schwarz, A. J., Stubbs, M., Stoyanova, R., Ballon, D., Howe, F. A., Koutcher, J. A., Leach, M. O., Griffiths, J. R., Heerschap, A., Glickson, J. D., Nelson, S. J., Evelhoch, J. L., Charles, H. C., Brown, T. R., Cruz-Lobo, J., Murphy-Boesch, J., ... Hu, J. (2006). In vivo 31 P MR spectral patterns and reproducibility in cancer patients studied in a multi-institutional trial. NMR in biomedicine, 19(4), 504-512. https://doi.org/10.1002/nbm.1057